Table 3.
Subgroup analysis of CRC incidence reduction after endoscopic screening
| Subgroups | No. of studies | Pooled RR (95% CI) | Z | P | Heterogeneity | |
|---|---|---|---|---|---|---|
| I2 (%) | Ph | |||||
| Intervention | 0.29 | |||||
| Screening 11,35,37,39,41,46,49,51 | 8 | 0.475 (0.418-0.540) | 5.57 | 0.000 | 71.4 | |
| Screening/diagnostic and Various* 36,40,43,44,47,48,50,54 | 8 | 0.498 (0.444-0.558) | 9.28 | 0.000 | 34.8 | |
| Study design | 0.28 | |||||
| Cochort 11,35-37,39,41,44,46,47,49 | 10 | 0.498 (0.444-0.558) | 9.52 | 0.000 | 27.6 | |
| (Nested) case-control 40,43,48,50,51,54 | 6 | 0.475 (0.418-0.540) | 5.28 | 0.000 | 78.0 | |
| Country | 0.02 | |||||
| Western 11,35,37,39-41,43,44,46-51,54 | 15 | 0.487 (0.446-0.532) | 9.62 | 0.000 | 60.5 | |
| Asia 36 | 1 | 0.500 (0.354-0.707) | 3.92 | 0.000 | NA | |
| Sample size | 0.24 | |||||
| ≤10,000 11,39,40,43,48-51 | 8 | 0.484 (0.424-0.553) | 5.23 | 0.000 | 72.0 | |
| 10,000-100,000 36,37,41,44,46,54 | 6 | 0.486 (0.431-0.547) | 8.14 | 0.000 | 51.3 | |
| ≥1 million 35,47 | 2 | 0.527 (0.380-0.730) | 3.86 | 0.000 | 0 | |
| Age | 0.01 | |||||
| 20-50 36,39,41,50,51 | 5 | 0.491 (0.431-0.558) | 4.46 | 0.000 | 82.0 | |
| ≥50 11,35,37,40,43,44,46-49,54 | 11 | 0.485 (0.433-0.544) | 10.23 | 0.000 | 24.6 | |
| Sex | 9.04 | |||||
| Male 36,40,47,48,52 | 5 | 0.473 (0.390-0.573) | 7.64 | 0.000 | 0.0 | |
| Female 36,37,47,48,52 | 5 | 0.702 (0.592-0.833) | 3.40 | 0.001 | 29.6 | |
NA = not applicable; RR = relative risk; CI = confidence interval.